Evidence map›Paper›PMID 39995503›Full record

ArticleIJID regions2025

HIV incidence and adherence after pre-exposure prophylaxis initiation in key populations in Indonesia: Findings from a real-world pilot program 2021-2023.

Nadia Hanum, Miasari Handayani, Armina Padmasawitri, Zulfan Zazuli, Kusnandar Anggadiredja, Mawar N Pohan, Tarinanda A Putri, Fani F Rakhmat, Dwi S Anggiani, Nurhalina Afriana and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in IJID regions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Nadia HanumDepartment of Pharmacology and Clinical Pharmacy, School of Pharmacy - Bandung Institute of Technology, Bandung, Indonesia.
Miasari HandayaniResearch Center for Care and Control of Infectious Disease - Padjajaran University, Bandung, Indonesia.
Armina PadmasawitriDepartment of Pharmacology and Clinical Pharmacy, School of Pharmacy - Bandung Institute of Technology, Bandung, Indonesia.
Zulfan ZazuliDepartment of Pharmacology and Clinical Pharmacy, School of Pharmacy - Bandung Institute of Technology, Bandung, Indonesia.
Kusnandar AnggadiredjaDepartment of Pharmacology and Clinical Pharmacy, School of Pharmacy - Bandung Institute of Technology, Bandung, Indonesia.
Mawar N PohanResearch Center for Care and Control of Infectious Disease - Padjajaran University, Bandung, Indonesia.
Tarinanda A PutriResearch Center for Care and Control of Infectious Disease - Padjajaran University, Bandung, Indonesia.
Fani F RakhmatResearch Center for Care and Control of Infectious Disease - Padjajaran University, Bandung, Indonesia.
Dwi S AnggianiHIV and STI Working Group of the Directorate General for Disease Prevention and Control - Indonesian Ministry of Health, Jakarta, Indonesia.
Nurhalina AfrianaHIV and STI Working Group of the Directorate General for Disease Prevention and Control - Indonesian Ministry of Health, Jakarta, Indonesia.
Endang LukitosariHIV and STI Working Group of the Directorate General for Disease Prevention and Control - Indonesian Ministry of Health, Jakarta, Indonesia.
Bagus R PrabowoThe Joint United Nations Programme on HIV/AIDS (UNAIDS), Jakarta, Indonesia.
Rudi WisaksanaResearch Center for Care and Control of Infectious Disease - Padjajaran University, Bandung, Indonesia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: To provide important data for the national rollout, Indonesia launched a pre-exposure prophylaxis (PrEP) pilot program. In this study, we determined the HIV incidence and adherence among key populations, PrEP initiation, sexually transmitted infection incidence, and changes in sexual behaviors. Methods: The Indonesian PrEP pilot program (December 2021 to December 2023, rolled out in 21 districts in 10 provinces) was a longitudinal, non-randomized implementation study among men who have sex with men, female sex workers, transgender women, people who inject drugs, and serodiscordant partners of people with HIV. Eligible participants were offered same-day oral PrEP and completed the baseline, 1-monthly, and 3-monthly follow-up visits. Results: A total of 9124 individuals initiated PrEP between December 2021 and December 2023; 4220 had at least one follow-up visit. Of the 4220, 31 seroconverted over 2817.5 person-years; overall incidence rate (IR) 1.10 (95% confidence interval 0.75-1.56) per 100 person-years. All seroconversions occurred during poor adherence or PrEP discontinuation (IR 7.8; 5.34-11.16 vs 0; 0-0.4 for adequate adherence). Event-driven PrEP users showed poorer adherence than daily PrEP users ( Conclusion: Insufficient adherence leads to decreased efficacy of PrEP. Improving adherence and access to PrEP is a public health priority in Indonesia.

Indexed as

HIV preventionIndonesiaKey populationsPre-exposure prophylaxisReal-world study

Identifiers

PMID39995503
PMCPMC11848754

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.